Phase 3 N=511 Experimental Medication For the Treatment of Generalized Anxiety Disorder
Anxiety Disorder
Primary: Change in HAM-A Total Score — -12.9; -15.7; -12.5 Units on a Scale — p=0.6540
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=69 Combined Treatment for Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Hamilton Anxiety Rating Scale (HAM-A) — 25.9; 23.8; 20.9; 19.4 units on a scale — p=.17
N/A N=76 A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: High End State Function — 56.52; 43.48; 56.52; 47.62 % people meeting high endstate status
Phase 3 N=402 Randomized Trial of Adult Participants With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the HAM-A Total Score at Week 8 — -9.28; -9.35 score on a scale — p=0.917
Phase 3 N=409 Generalized Anxiety Disorder Adjunct Study
Anxiety · Anxiety Disorders · Anxiety Neuroses
Primary: Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.74; -9.61 units on scale
N/A N=64 Cognitive-behavioral Therapy for Generalized Anxiety Disorder in Primary Care
Generalized Anxiety Disorder
Primary: Penn State Worry Questionnaire - Measure of Symptom Change — 42.1; 55.8 score on a scale — p=<0.05
Phase 4 N=25 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)
Generalized Anxiety Disorder
Primary: Change in Hamilton Anxiety Rating Scale Score — -6.4 units on a scale
N/A N=30 Exercise Training for the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Generalized Anxiety Disorder (GAD) Remission as Measured by Anxiety Disorders Interview Schedule-Adult Version (ADIS-IV) Severity Ratings — 4; 6; 7 Participants
Phase 3 N=495 EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder (GAD)
Primary: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42) — -9.01; -8.93 Score on scale
Phase 4 N=32 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Signal Change in Brain Activity in the Amygdala When Viewing Emotional Faces — .1489; .1074; .0119; .1404 Percent signal change in brain acitivity
Phase 4 N=30 Escitalopram in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Effect of Escitalopram After 8 Weeks of Treatment in Patients With GAD Using the Hamilton Anxiety Scale (HAMA) — 13.1 scores on a scale
Phase 3 N=210 Duloxetine for the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint — 12.76; 13.56; -6.38; -5.29 Units on a scale — p=0.006
Phase 2 N=239 Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed — 25.5; 25.6; 25.5; 25.8 score on a scale
N/A N=7 Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Clinician's Severity Rating (CSR) Scale of Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) — 5.5; 3.14; 2.43 units on a scale
Phase 2 N=369 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
Anxiety Disorders
Primary: Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.1; -10.4; -10.8; -9.5 Units on scale
Phase 4 N=615 Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 — 25.8; 24.9; 24.4; -7.7 units on a scale
N/A N=73 Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults
Generalized Anxiety Disorder
Primary: Hamilton Anxiety Rating Scale — 18; 15; 14; 8 participants — p=<.001
Phase 2 N=456 Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
Generalized Anxiety Disorder
Primary: Change From Baseline to Week 8 in the Total Score on the Hamilton Anxiety Scale (HAM-A), as Assessed by the Site-trained Rater — -10.0; -9.3; -9.5 Units on a scale
Phase 4 N=89 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
Generalized Anxiety Disorder
Primary: Active Symptoms of Generalized Anxiety Disorder — 13.65; 16.27 units on a scale
Phase 4 N=42 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
Generalized Anxiety Disorder
Primary: Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg — 10.638; 10.008…
Phase 3 N=281 A Study in Pediatric Participants With Generalized Anxiety Disorder
Anxiety Neuroses · Anxiety States, Neurotic · Neuroses, Anxiety
Primary: Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety…
N/A N=26 Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) at Post-treatment and 3-month Follow-up. — 25.31; 20.75; 12.10; 14.38 units on a…
N/A N=141 Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Changes From Baseline in Penn State Worry Questionnaire (PSWQ-A) at Week 13 — -9.44; -5.37 units on a scale
Phase 3 N=404 Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 14.7; 11.3 Score on Scale — p=0.0048
N/A N=226 GATE: Generalized Anxiety - A Treatment Evaluation
Generalized Anxiety Disorder
Primary: Proportion of Participants With Treatment Response — 0.54; 0.71; 0.33 Proportion of participants — p=.03
Phase 4 N=49 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
Bipolar Disorder · Panic Disorder · Generalized Anxiety Disorder
Primary: Clinician Global Improvement Scale (CGI-21) — 7.8; 3.4 units on a scale
Phase 4 N=181 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
Social Phobia
Primary: Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders — 17; 11; 10 participants
Phase 4 N=418 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Generalized Anxiety Disorder · Panic Disorder
Primary: Cumulative Percent of Participants Showing a Response in the Symptoms of Anxiety (Decrease in Total Hamilton Anxiety (HAM-A) -Score of >=50%) in the Intent-to-treat…
Phase 3 N=673 Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 13.1; 12.0; 11.2 Score on scale — p=0.0830
Phase 3 N=398 Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — 14.9; 13.5 Score on Scale — p=0.0438